Short answer
Twist Bioscience Corp (TWST) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Twist Bioscience results for quarter and fiscal year ended September 30, 2026.
Twist Bioscience Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Twist Bioscience results for quarter and fiscal year ended September 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
- Fiscal-year reporting provides investors an update on operating performance and year-end financial position
Item EX-99.1 · Exhibit EX-99.1
- Fiscal 2026 revenue $459.4M, up 22%, with DSPS up 31.7% and NGS up 14.1%
- Q4 revenue $126.6M, up 28%, marking the 15th consecutive quarter of sequential growth
- Gross margin improved to 52.4% from 50.7%, while Q4 adjusted EBITDA turned positive at $2.2M
- Fiscal 2026 net loss widened to $130.2M, partly reflecting $7.2M litigation costs and the prior-year $48.8M business-sale gain
- Fiscal 2027 guidance: revenue $550M-$560M, gross margin 52.5%-53%, positive adjusted EBITDA, and $75M capital expenditures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Twist Bioscience Corp 8-K filings
Get the next TWST 8-K as it lands
Follow TWST for push alerts, or ask the research agent what this filing means.